Skip to main
TNDM
TNDM logo

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 30%
Buy 30%
Hold 37%
Sell 3%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is experiencing significant growth, as indicated by a 20.6% year-over-year increase in top-line revenue, reaching $252.4 million, surpassing consensus expectations. The company is well-positioned for future expansion with a robust product pipeline and the recent FDA clearance for Type 2 diabetes, effectively doubling its addressable market in the U.S. Furthermore, customer satisfaction and strong retention rates underpin a solid foundation for sustained, double-digit revenue growth, supported by increasing warranty renewals and supply sales.

Bears say

Tandem Diabetes Care has experienced substantial operating losses since its inception, casting doubt on its ability to achieve sustained profitability. The company's recent guidance for 2025 indicates weaker-than-expected sales trends, challenges with expanding market share for its Mobi pump, and potential risks from competitive pressures and reimbursement issues, all contributing to a negative outlook. Additionally, the company's gross margins fell short of consensus expectations, and the stock experienced a significant decline of approximately 19% in after-hours trading, further reflecting market concerns about its financial health and growth prospects.

TNDM has been analyzed by 30 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 30% recommend Buy, 37% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 30 analysts, TNDM has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.